Jiangfan Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiangfan Zhu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
An An Xu
Department of Minimally Invasive Surgery, East Hospital, Tongji University, School of Medicine, Shanghai 200120, China
4 shared publicationsHai Hu
East Hospital of Tongji University, Shanghai, People’s Republic of China
4 shared publicationsYing Zhang Ma
East Hospital of Tongji University, Shanghai, People’s Republic of China
4 shared publicationsCheng-Li Song
2 shared publicationsDong-Sheng Zhang
2 shared publicationsMan Zhu Xu
East Hospital of TongJi University
2 shared publications
Latest Publications
- Open Access
- 16 October 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (11) , 3941-3943
Extended Length of Stay After Bariatric Surgery in China: Advantage or Disadvantage?
- 16 October 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (11) , 3941-3943
Open AccessExtended Length of Stay After Bariatric Surgery in China: Advantage or Disadvantage?
- 25 March 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (5) , 1961-1963
Kill Three Birds with One Stone: Sleeve Reduction, Cruroplasty, Gastropexy, and Concomitant Sleeve Ileal Bypass for Patients with Gastroesophageal Reflux, Constipation, and Weight Regain After Laparoscopic Sleeve Gastrectomy
- 25 March 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (5) , 1961-1963
Kill Three Birds with One Stone: Sleeve Reduction, Cruroplasty, Gastropexy, and Concomitant Sleeve Ileal Bypass for Patients with Gastroesophageal Reflux, Constipation, and Weight Regain After Laparoscopic Sleeve Gastrectomy
- 6 March 2023
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (5) , 1598-1599
The Ratio of Common Limb and Total Bowel Length Could Be Used in Determination of Anastomotic Position in Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy
- 6 March 2023
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (5) , 1598-1599
The Ratio of Common Limb and Total Bowel Length Could Be Used in Determination of Anastomotic Position in Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy
- 4 June 2022
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 21 (4) , 272-732
MiR-494-3p mediates oxaliplatin resistance of colorectal cancer cells via PTEN/AKT pathway
Purpose: To unravel the influence of miR-494-3p on the insensitivity of colorectal cancer (CRC) cells to oxaliplatin. Methods: The mRNA level of miR-494-3p in oxaliplatin-resistant HT-29 cells was evaluated with reverse transcript-polymerase chain reaction (RT-PCR). The cells were treated with miR-494-3p suppressor or mimic, and then apoptotic changes were determined flow cytometrically. Resistancerelated gene expressions were measured using RT-PCR and western blotting. In addition, in vivo mouse experiments were conducted. Results: MiR-494-3p expression in oxaliplatin-resistant HT-29 cells was much higher than that in parental HT-29 cells, accompanied by increased levels of MRP, P-gp, and AKT phosphorylation (p-AKT), and decreased phosphatase and tensin homolog (PTEN) (p < 0.001). The miR-494-3p mimic suppressed oxaliplatin-induced parental HT-29 cell apoptosis, while miR-494-3p inhibitor promoted oxaliplatin-resistant HT-29 cell apoptosis and decreased the levels of p-AKT, MRP and P-gp, while upregulating PTEN (p < 0.001). Furthermore, AKT inhibitor had similar effects as miR-494-3p inhibitor (p < 0.001). Experiments using nude mice demonstrated that inhibition of miR-494-3p accentuated the sensitivity of oxaliplatin-resistant HT-29 cells to oxaliplatin (p < 0.05). Conclusion: Suppression of miR-494-3p attenuates oxaliplatin insensitivity to CRC cells via a mechanism which may involve PTEN/AKT pathway. Therefore, miR-494-3p may be an effective target for overcoming drug resistance of CRC.
- 4 June 2022
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 21 (4) , 272-732
MiR-494-3p mediates oxaliplatin resistance of colorectal cancer cells via PTEN/AKT pathway
Purpose: To unravel the influence of miR-494-3p on the insensitivity of colorectal cancer (CRC) cells to oxaliplatin. Methods: The mRNA level of miR-494-3p in oxaliplatin-resistant HT-29 cells was evaluated with reverse transcript-polymerase chain reaction (RT-PCR). The cells were treated with miR-494-3p suppressor or mimic, and then apoptotic changes were determined flow cytometrically. Resistancerelated gene expressions were measured using RT-PCR and western blotting. In addition, in vivo mouse experiments were conducted. Results: MiR-494-3p expression in oxaliplatin-resistant HT-29 cells was much higher than that in parental HT-29 cells, accompanied by increased levels of MRP, P-gp, and AKT phosphorylation (p-AKT), and decreased phosphatase and tensin homolog (PTEN) (p < 0.001). The miR-494-3p mimic suppressed oxaliplatin-induced parental HT-29 cell apoptosis, while miR-494-3p inhibitor promoted oxaliplatin-resistant HT-29 cell apoptosis and decreased the levels of p-AKT, MRP and P-gp, while upregulating PTEN (p < 0.001). Furthermore, AKT inhibitor had similar effects as miR-494-3p inhibitor (p < 0.001). Experiments using nude mice demonstrated that inhibition of miR-494-3p accentuated the sensitivity of oxaliplatin-resistant HT-29 cells to oxaliplatin (p < 0.05). Conclusion: Suppression of miR-494-3p attenuates oxaliplatin insensitivity to CRC cells via a mechanism which may involve PTEN/AKT pathway. Therefore, miR-494-3p may be an effective target for overcoming drug resistance of CRC.
- 14 March 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (7) , 2463-2464
Suture or Not Suture: is Staple Line Reinforcement Necessary in Laparoscopic Sleeve Gastrectomy?
- 14 March 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (7) , 2463-2464
Suture or Not Suture: is Staple Line Reinforcement Necessary in Laparoscopic Sleeve Gastrectomy?
- 24 June 2021
- Published by Springer Nature in Obesity Surgery
- Vol. 31 (10) , 4647-4648
Laparoscopic Re-sleeve Gastrectomy with Single Anastomosis Duodenoileal Switch (RS-SADIS) for Weight Regain or Unsatisfied Weight Loss After Initial Sleeve Gastrectomy
- 24 June 2021
- Published by Springer Nature in Obesity Surgery
- Vol. 31 (10) , 4647-4648
Laparoscopic Re-sleeve Gastrectomy with Single Anastomosis Duodenoileal Switch (RS-SADIS) for Weight Regain or Unsatisfied Weight Loss After Initial Sleeve Gastrectomy
- 29 September 2018
- Published by Springer Nature in Obesity Surgery
- Vol. 29 (1) , 297-298
Bariatric Surgery for a Patient with Kennedy’s Disease
- 29 September 2018
- Published by Springer Nature in Obesity Surgery
- Vol. 29 (1) , 297-298
Bariatric Surgery for a Patient with Kennedy’s Disease
- 13 April 2016
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (7) , 1639-1641
The Mechanism of Metabolic Surgery: Gastric Center Hypothesis
Background There is growing evidence that bariatric surgery can lead to remission of metabolic syndrome. But the mechanism by which bariatric surgery alleviates metabolic syndrome is unclear. Materials and Methods Several present hypotheses which include decreased caloric intake following the surgeries, foregut and hindgut hypothesis, bile acid and bacterial flora changes, and proposed gastric center hypothesis were discussed. Results None of the currently available hypotheses is solely capable to lead to a reasonable explanation regarding improvement of metabolic syndrome by various bariatric surgical procedures. Proposed gastric center hypothesis could give a better explanation of the mechanism. Conclusions All the present bariatric surgeries are involved in changes of the stomach. There could be some particular cells on the stomach, which could secrete unknown special hormones, and then lead to control the metabolic process.
- 13 April 2016
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (7) , 1639-1641
The Mechanism of Metabolic Surgery: Gastric Center Hypothesis
Background There is growing evidence that bariatric surgery can lead to remission of metabolic syndrome. But the mechanism by which bariatric surgery alleviates metabolic syndrome is unclear. Materials and Methods Several present hypotheses which include decreased caloric intake following the surgeries, foregut and hindgut hypothesis, bile acid and bacterial flora changes, and proposed gastric center hypothesis were discussed. Results None of the currently available hypotheses is solely capable to lead to a reasonable explanation regarding improvement of metabolic syndrome by various bariatric surgical procedures. Proposed gastric center hypothesis could give a better explanation of the mechanism. Conclusions All the present bariatric surgeries are involved in changes of the stomach. There could be some particular cells on the stomach, which could secrete unknown special hormones, and then lead to control the metabolic process.
- 23 July 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (4) , 797-804
Effect of Sleeve Gastrectomy Plus Side-to-Side Jejunoileal Anastomosis for Type 2 Diabetes Control in an Obese Rat Model
Sleeve gastrectomy plus side-to-side jejunoileal anastomosis (JI-SG), a relatively new approach to bariatric surgeries, has shown promising results for treating obesity and metabolic comorbidities. This study investigated the feasibility and safety of JI-SG in weight loss and diabetes remission compared with sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Forty 10-week-old male Zucker diabetic fatty rats were randomly assigned to four groups: control, SG, JI-SG, and RYGB. Their body weights, food intake, and levels of gut hormones (ghrelin, insulin, and glucagon-like peptide-1 (GLP-1)) and lipids were measured. Rats in the SG, JI-SG, and RYGB groups demonstrated lower food intake and more weight loss 2 weeks postoperatively compared with control rats. Furthermore, rats in the JI-SG group achieved more weight loss (mean 242.7 ± 11.2 g) compared with those in the SG and RYGB groups (SG, 401.4 ± 15.1 g and RYGB, 298 ± 12 g, both P < 0.01). All surgery groups demonstrated a decreased fasting insulin, serum glucose, lipid levels, and increased GLP-1 postoperatively. The JI-SG group had lower fasting ghrelin levels than the RYGB group (168 ± 19.8 ng/L vs. 182 ± 16.7 ng/L, P < 0.01) and higher fasting GLP-1 levels than the SG group (1.99 ± 0.11 pmol/L vs. 1.71 ± 0.12 pmol/L, P < 0.01) at 12 weeks postoperatively. Over the experimental period, the ghrelin levels slowly increased in all surgical groups but remained lower than the preoperative and control levels. JI-SG induced higher ghrelin and GLP-1 levels and improved glycemic control in Zucker diabetic fatty rats. Compared with SG and RYGB, JI-SG appeared to be a simple, relatively safe, and more effective procedure for treating type 2 diabetes and obesity in this animal model.
- 23 July 2015
- Published by Springer Nature in Obesity Surgery
- Vol. 26 (4) , 797-804
Effect of Sleeve Gastrectomy Plus Side-to-Side Jejunoileal Anastomosis for Type 2 Diabetes Control in an Obese Rat Model
Sleeve gastrectomy plus side-to-side jejunoileal anastomosis (JI-SG), a relatively new approach to bariatric surgeries, has shown promising results for treating obesity and metabolic comorbidities. This study investigated the feasibility and safety of JI-SG in weight loss and diabetes remission compared with sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Forty 10-week-old male Zucker diabetic fatty rats were randomly assigned to four groups: control, SG, JI-SG, and RYGB. Their body weights, food intake, and levels of gut hormones (ghrelin, insulin, and glucagon-like peptide-1 (GLP-1)) and lipids were measured. Rats in the SG, JI-SG, and RYGB groups demonstrated lower food intake and more weight loss 2 weeks postoperatively compared with control rats. Furthermore, rats in the JI-SG group achieved more weight loss (mean 242.7 ± 11.2 g) compared with those in the SG and RYGB groups (SG, 401.4 ± 15.1 g and RYGB, 298 ± 12 g, both P < 0.01). All surgery groups demonstrated a decreased fasting insulin, serum glucose, lipid levels, and increased GLP-1 postoperatively. The JI-SG group had lower fasting ghrelin levels than the RYGB group (168 ± 19.8 ng/L vs. 182 ± 16.7 ng/L, P < 0.01) and higher fasting GLP-1 levels than the SG group (1.99 ± 0.11 pmol/L vs. 1.71 ± 0.12 pmol/L, P < 0.01) at 12 weeks postoperatively. Over the experimental period, the ghrelin levels slowly increased in all surgical groups but remained lower than the preoperative and control levels. JI-SG induced higher ghrelin and GLP-1 levels and improved glycemic control in Zucker diabetic fatty rats. Compared with SG and RYGB, JI-SG appeared to be a simple, relatively safe, and more effective procedure for treating type 2 diabetes and obesity in this animal model.